Form PTO-1449 **INFORMATION DISCLOSURE CITATION IN AN APPLICATION** *(Use several sheets if necessary)*	Docket Number (Optional) ERM-105.01	Application Number 10/072,830
	Applicant Chen, et. al.	
	Filing Date February 8, 2002	Group Art Unit 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OC	A1	5,744,499	04/28/1998	Quash et al.	514	639	12/28/1995

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	Translation NO
OC	B1	WO 94/27426	12/08/1994	PCT				
OC	B2	WO 98/02178	01/22/1998	PCT				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

	C1	Dubois-Dauphin et al., (1994), Neonatal motoneurons overexpressing the *bcl-2* protooncogene in transgenic mice are protected from axotomy-induced cell death, *Proc. Natl. Acad. Sci. USA* Vol. 91, pp. 3309-3313
	C2	Sato et al., (1994), Neuronal Differentiation of PC12 Cells as a Result of Prevention of Cell Death by *bcl-2*, *Journal of Neurobiology* Vol. 25, No. 10, pp. 1227-1234
	C3	Martinou et al., (1994), Overexpression of BCL-2 in Transgenic Mice Protects Neurons from Naturally Occurring Cell Death and Experimental Ischemia, *Neuron* Vol. 13, pp. 1017-1029
	C4	Farlie et al., (1995), *bcl-2* transgene expression can protect neurons against developmental and induced cell death, *Proc. Natl. Acad. Sci. USA* Vol. 92, pp. 4397-4401
	C5	Chen et al., (1995), Intrinsic changes in developing retinal neurons result in regenerative failure of their axons, *Proc. Natl. Acad. Sci. USA*, Vo. 92, pp. 7287-7291
	C6	Linnik et al., (1995), Expression of bcl-2 From a Defective Herpes Simplex Virus-1 Vector Limits Neuronal Death in Focal Cerebral Ischemia, *Stroke, A Journal of Cerebral Circulation*, Vol. 26, No. 9, pp. 1670-1675
	C7	Frankowski et al., (1995), Function and expression of the Bcl-x gene in the developing and adult nervous system, *NeuroReport*, Vol. 6, pp. 1917-1921
OC	C8	Sagot et al., (1995), Bcl-2 Overexpression Prevents Motoneuron Cell Body Loss but Not Axonal Degeneration in a Mouse Model of a Neurodegenerative Disease, *The Journal of Neuroscience*, Vol. 15, No. 11, pp 7727-7733
	C9	Lawrence et al., (1996), Overexpression of Bcl-2 with Herpes Simplex Virus Vectors Protects CNS Neurons against Neurological Insults In Vitro and In Vivo, *The Journal of Neuroscience*, Vol. 16, No. 2, pp. 486-496
	C10	Burne et al., (1996), Glial Cells Are Increased Proportionally in Transgenic Optic Nerves with Increased Numbers of Axons, *The Journal of Neuroscience*, Vol. 16, pp. 2064-2073
	C11	Sagot et al., (1996), GDNF Slows Loss of Motoneurons but Not Axonal Degeneration or Premature Death of pmn/pmn Mice, *The Journal of Neuroscience*, Vol. 16, No. 7, pp. 2335-2341
	C12	Zhang et al., (1996), BCL2 regulates neural differentiation, *Proc. Natl. Acad. Sci. USA*, Vol. 93, pp. 4504-4508
	C13	Gillardon et al., (1996), Expression pattern of candidate cell death effector proteins BAX, Bcl-2, Bcl-X, and c-Jun in sensory and motor neurons following sciatic nerve transection in the rat, *Brain Research*, Vol. 739, pp. 244-250
	C14	Harada et al., (1996) Characterization of Inhibition by Chronic Treatment with Lithium Ion on Nerve Growth Factor-Induced Neronal Differentiation of Rat PC12 Pheochromocytoma Cells, *Journal of Toxicology and Environmental Health*, Vol. 49, pp 197-206
	C15	Chen et al., (1997), Bcl-2 promotes regeneration of severed axons in mammalian CNS, *Nature*, Vol. 385, pp. 434-439
	C16	Yves-Alain Barde, (1997), Help from within for damaged axons, *Nature*, Vol. 385, pp. 391 & 393
	C17	Isenmann et. al., (1997), Up-regulation of Bax Protein in Degenerating Retinal Ganglion Cells Precedes Apoptotic Cell Death after Optic Nerve Lesion in the Rat, *European Journal of Neuroscience*, Vol. 9, pp. 1736-1772
	C18	Chen et al., (1999), Long Term Lithium Treatment Suppresses p53 and Bax Expression but Increases Bcl-2 Expression, *The Journal of Biological Chemistry*, Vol. 274, No. 10, pp. 6039-6042

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)	Application Number
ERM-105.01	10/072,830
Applicant	
Chen, et. al.	
Filing Date	**Group Art Unit**
February 8, 2002	~~1633~~ 1646

	C19	Chierzi et al., (1999), Optic Nerve Crush: Axonal Responses in Wild-Type and bcl-2 Transgenic Mice, *The Journal of Neuroscience*, Vol. 19, No. 19, pp. 8367-8376
	C20	Manji et al., (1999), Lithium at 50: Have the Neuroprotetive Effects of This unique Cation Been Overlooked? *Society of Biological Psychiatry*, Vol. 46, pp. 929-940
	C21	Matsuoka et al. (1999), Adenovirus-mediated gene transfer of Bcl-xL prevents cell death in primary neuronal culture of the rat, *Neuroscience Letters*, Vol. 270, pp. 177-180
	C22	Chen et al. (2000), Enhancement of Hippocampal Neurogenesis by Lithium, *Journal of Neurochemistry*, Vol. 75, No. 4, pp. 1729-1734
oc	C23	Shinoura et al., (2000), Adenovirus-Mediated Trasfer of Bcl-X_L Protects Neuronal Cells from Bax-Induced Apoptosis, *Experimental Cell Research*, Vol. 254, pp. 221-231
	C24	Manji et al., (2000), Lithium Up-Regulates the Cytoprotective Protein Bcl-2 in the CNS In Vivo: A Role for Neurotrophic and Neuroprotective Effects in Manic Depressive Illness, *J. Clin. Psychiatry*, Vol. 61, pp. 82-96
	C25	Middleton et al., (2001), Reciprocal developmental changes in the roles of Bcl-w and Bcl-X_L in regulating sensory neuron survival, *Development*, Vol. 128, pp. 447-457
	C26	Kahn et al., Guideline 1: Selecting a Mood Stabilizer for Acute Phase Treatment of Manic, Mixed, and Hypomanic Episodes, *The Expert Consensus Guideline Series: Treatment of Bipolar Disorder*. pp. 3-4, www.psychguides.com
not present	C27	~~Drug Monograph, Lithium Carbonate, *Internet Mental Health*, pp. 1-7, www.mentalhealth.com~~
	C28	~~Search Report from The International Searching Authority~~

EXAMINER	DATE CONSIDERED
	10/01/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE